Results 211 to 220 of about 22,609,350 (346)

Clinical and genetic features of CTLA-4 haploinsufficiency: a prospective study in China. [PDF]

BMC Rheumatol
Liu G, Zhang J, Wu D, Xu J, Dai J, Shen M.   +5 more
europepmc   +1 more source

INFLUENCE OF THE CTLA-4 (RS231775) GENE POLYMORPHISM ON THE DEGREE OF THE THYROID GLAND ENLARGEMENT IN PATIENTS OPERATED FOR NODULAR GOITER SECONDARY TO AUTOIMMUNE THYROIDITIS

, 2017
Objectives: To analyze the influence of the CTLA-4(+49G/A)rs231775 gene polymorphism on the degree of thyroid gland enlargement in patients operated for nodular goiter secondary to autoimmune thyroiditis (NGAIT) and thyroid adenomas (TA).
Kristina A. Chympoi, Larysa P. Sydorchuk, Oleksandr V. Shidlovskyi, Nina P. Tkachuk, Volodymyr V. Bezruk, Marina D. Gresko, Viktor O. Shidlovskyi, Victor M. Batig, Michael I. Sheremet, Tetyana O. Bezruk, Anatoly D. Bedenyuk, Vitaliy V. Maksymyuk   +11 more
core  

Losartan Enhances Radiosensitivity by Reversing Immunosuppressive Tumor Microenvironment Induced by Radiotherapy in TNBC

Cancer Science, EarlyView.
Our study demonstrates that the angiotensin receptor blocker losartan enhances the efficacy of radiotherapy in triple‐negative breast cancer by reversing the immunosuppressive tumor microenvironment. Losartan reprograms tumor‐associated macrophages, inhibits myeloid‐derived suppressor cell function, and boosts CD8+ T‐cell activity.
Xu Wang, Cuiwei Liu, Zihan Xia, Ting Hu, Yuting Li, Dan Han, Yunjie Song, Yuxi Ma, Yanxia Zhao   +8 more
wiley   +1 more source

Potentiation of the altered immune microenvironment following RF ablation of murine distant tumors with CTLA-4 immunotherapy. [PDF]

Eur Radiol Exp
Zhao K, Shen Y, Yang W, Wu H, Wang B, Wang W, Wu W, Yan K, Goldberg SN.   +8 more
europepmc   +1 more source

Triple‐Mutated HSV‐1 Expressing Soluble B7‐1 Plus CTLA‐4 Blockade Suppresses Lymph Node Metastasis in Tongue Cancer

Cancer Science, EarlyView.
In murine tongue cancer models, T‐mB7‐1, a triple‐mutated oncolytic herpes simplex virus type 1 (HSV‐1) engineered to express soluble B7‐1, suppresses cervical lymph node metastasis and improves survival, addressing a major prognostic determinant in oral squamous cell carcinoma (OSCC).
Akinari Sugauchi, Toshihiro Uchihashi, Hirotaka Ito, Miwako Iwai, Yuzuri Tsurumaki Sato, Kyoko Kurioka, Sena Zeynep Usta, Minoru Tanaka, Mikihiko Kogo, Susumu Tanaka, Hiroshi Fukuhara, Tomoki Todo   +11 more
wiley   +1 more source

Design and Characterization of Prodrugged Anti-CTLA-4 Antibodies. [PDF]

Chembiochem
Yamazoe S, Huber M, Kotapati S, Akter R, Jashnani A, Deol S, Bee C, Engelhart J, Poudel YB, Krystek S, Haugner J, Srinivasan M, Rajpal A, Zhang Y, Strop P, Rao C.   +15 more
europepmc   +1 more source

Tumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐PD‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
New antibody‐based sandwich assays to measure plasma extracellular vesicle (EV) subsets derived from tumor tissues were developed. These EVs can be easily measured repeatedly at appropriate times. They may be useful as liquid biopsies for early cancer detection and for predicting efficacy following surgery and anti‐PD‐1 antibody in NSCLC patients ...
Tomonari Kinoshita, Shigeki Ohta, Seiki Wakui, Chihaya Maeda, Yuichiro Hayashi, Aya Misawa, Ryosuke Satomi, Shinnosuke Ikemura, Kenzo Soejima, Tomonori Yaguchi, Shotaro Maruyama, Hiroshi Kagamu, Yutaka Kawakami   +12 more
wiley   +1 more source

Immune dysregulation from a novel CTLA-4 haploinsufficiency variant. [PDF]

J Hum Immun
Brodsky NN, Kennedy A, Glaser D, Jeffries L, Ji W, Natarajan E, Shin JJ, Sansom DM, Lucas CL, Lakhani SA.   +9 more
europepmc   +1 more source

MAPK Inhibitor‐Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities

Cancer Science, EarlyView.
Melanoma response to MAPK inhibition progresses from drug‐sensitive cells to drug‐tolerant persister states, which enable survival through adaptive signaling, metabolic rewiring, and phenotypic plasticity. These persister cells serve as an intermediate reservoir from which resistant tumors ultimately emerge. ABSTRACT Though major advancements have been
Bhoomi Shah, Mackenzie M. Mayhew, Jacob Sellers, Russell G. Witt   +3 more
wiley   +1 more source

First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies. [PDF]

ESMO Open
Ekström-Rydén V, Carneiro A, Yachnin J, Staal Rohrberg K, Enell Smith K, Ellmark P, Løvendahl Eefsen R, Ullenhag GJ.   +7 more
europepmc   +1 more source